Australia-based radiopharmaceutical company Telix Pharmaceuticals has created a new radionuclide generator that could facilitate the commercial supply of lead-212 isotope-based therapies.

The system uses a simple radionuclide generator to repeatedly separate thorium-226 from its longer-lived parent isotope, uranium-230. Both of these isotopes emit radioactive alpha particles.

Eckert & Ziegler has submitted its documents for the gallium generator to the U.S. Food and Drug Administration (FDA), establishing a Drug Master File (DMF no. 28741) with the agency.

Radionuclides and/or radiopharmaceuticals are prepared in hot labs by nuclear medicine technologists. The molybdenum-technetium 99 Mo/ 99m Tc-generator is used as a primary source in hot labs to ...

BERLIN, Germany - (NewMediaWire) - August 5, 2024 - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide ...

Specific objectives of the research project were (a) to study the performance of the 188W/188Re and 90Sr/90Y generators characterized by a prolonged shelf life as a result of the relatively long-lived ...

Clovis holds U.S. and global rights for FAP-2286 excluding Europe, Russia, Turkey, and Israel. FAP-2286 is an unlicensed medical product. About Targeted Radionuclide Therapy ...

How the therapy works The biological action of a radiopharmaceutical is determined by the form of ionizing radiation emitted by the radionuclide. While imaging procedures in nuclear medicine require ...

The issuer is solely responsible for the content of this announcement. August 5, 2024 - Berlin - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission ...